Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPALA
PACTR202301600757432Phase 3Recruiting
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV), sponsored by MRC/UVRI and LSHTM Uganda Research Unit. Primary endpoint: HIV-1 viral load at 12 months. Started Nov 2022; status: recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202301600757432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202301600757432.